Advertisement
Loading...

Clene Inc.

CLNNNASDAQ
Healthcare
Biotechnology
$7.05
$0.55(8.46%)
U.S. Market opens in 13h 45m

Clene Inc. Fundamental Analysis

Clene Inc. (CLNN) shows weak financial fundamentals with a PE ratio of -2.36, profit margin of -250.10%, and ROE of 2.34%. The company generates $0.0B in annual revenue with weak year-over-year growth of -41.52%.

Key Strengths

PEG Ratio-0.16
Current Ratio1.94

Areas of Concern

ROE2.34%
Operating Margin-157.22%
We analyze CLNN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -18739.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-18739.8/100

We analyze CLNN's fundamental strength across five key dimensions:

Efficiency Score

Weak

CLNN struggles to generate sufficient returns from assets.

ROA > 10%
-1.55%

Valuation Score

Excellent

CLNN trades at attractive valuation levels.

PE < 25
-2.36
PEG Ratio < 2
-0.16

Growth Score

Moderate

CLNN shows steady but slowing expansion.

Revenue Growth > 5%
-41.52%
EPS Growth > 10%
53.26%

Financial Health Score

Excellent

CLNN maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.17
Current Ratio > 1
1.94

Profitability Score

Weak

CLNN struggles to sustain strong margins.

ROE > 15%
233.93%
Net Margin ≥ 15%
-250.10%
Positive Free Cash Flow
No

Key Financial Metrics

Is CLNN Expensive or Cheap?

P/E Ratio

CLNN trades at -2.36 times earnings. This suggests potential undervaluation.

-2.36

PEG Ratio

When adjusting for growth, CLNN's PEG of -0.16 indicates potential undervaluation.

-0.16

Price to Book

The market values Clene Inc. at -4.20 times its book value. This may indicate undervaluation.

-4.20

EV/EBITDA

Enterprise value stands at -2.16 times EBITDA. This is generally considered low.

-2.16

How Well Does CLNN Make Money?

Net Profit Margin

For every $100 in sales, Clene Inc. keeps $-250.10 as profit after all expenses.

-250.10%

Operating Margin

Core operations generate -157.22 in profit for every $100 in revenue, before interest and taxes.

-157.22%

ROE

Management delivers $2.34 in profit for every $100 of shareholder equity.

2.34%

ROA

Clene Inc. generates $-1.55 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.55%

Following the Money - Real Cash Generation

Operating Cash Flow

Clene Inc. generates limited operating cash flow of $-15.93M, signaling weaker underlying cash strength.

$-15.93M

Free Cash Flow

Clene Inc. generates weak or negative free cash flow of $-15.96M, restricting financial flexibility.

$-15.96M

FCF Per Share

Each share generates $-1.60 in free cash annually.

$-1.60

FCF Yield

CLNN converts -27.29% of its market value into free cash.

-27.29%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.36

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.16

vs 25 benchmark

P/B Ratio

Price to book value ratio

-4.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

505.97

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.17

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

2.34

vs 25 benchmark

ROA

Return on assets percentage

-1.55

vs 25 benchmark

ROCE

Return on capital employed

-1.41

vs 25 benchmark

How CLNN Stacks Against Its Sector Peers

MetricCLNN ValueSector AveragePerformance
P/E Ratio-2.3629.36 Better (Cheaper)
ROE233.93%733.00% Weak
Net Margin-25009.70%-42369.00% (disorted) Weak
Debt/Equity-1.170.46 Strong (Low Leverage)
Current Ratio1.944.35 Neutral
ROA-154.69%-16668.00% (disorted) Weak

CLNN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Clene Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-65.53%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

51.79%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

65.21%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ